Objectives: To employ metabolomics-based pathway and network analyses to evaluate the cerebrospinal fluid metabolome after severe traumatic brain injury in children and the capacity of combination therapy with probenecid and N-acetylcysteine to impact glutathione-related and other pathways and networks, relative to placebo treatment. Design: Analysis of cerebrospinal fluid obtained from children enrolled in an Institutional Review Board-approved, randomized, placebo-controlled trial of a combination of probenecid and N-acetylcysteine after severe traumatic brain injury (Trial Registration NCT01322009). Setting: Thirty-six-bed PICU in a university-affiliated children's hospital. Patients and Subjects: Twelve children 2-18 years old after severe traumatic brain injury and five age-matched control subjects. Intervention: Probenecid (25 mg/kg) and N-acetylcysteine (140 mg/kg) or placebo administered via naso/orogastric tube. Measurements and Main Results: The cerebrospinal fluid metabolome was analyzed in samples from traumatic brain injury patients 24 hours after the first dose of drugs or placebo and control subjects. Feature detection, retention time, alignment, annotation, and principal component analysis and statistical analysis were conducted using XCMS-online. The software "mummichog" was used for pathway and network analyses. A two-component principal component analysis revealed clustering of each of the groups, with distinct metabolomics signatures. Several novel pathways with plausible mechanistic involvement in traumatic brain injury were identified. A combination of metabolomics and pathway/ network analyses showed that seven glutathione-centered pathways and two networks were enriched in the cerebrospinal fluid of traumatic brain injury patients treated with probenecid and N-acetylcysteine versus placebo-treated patients. Several additional pathways/networks consisting of components that are known substrates of probenecid-inhibitable transporters were also identified, providing additional mechanistic validation. Conclusions: This proof-of-concept neuropharmacometabolomics assessment reveals alterations in known and previously unidentified metabolic pathways and supports therapeutic target
T he biochemical milieu of the CNS is dynamic and tightly regulated and can be explored using metabolomics (1) . Metabolomics systematically identifies and quantifies the inventory of small molecule metabolites altered by biochemical and cellular processes at a specific time point and has recently been used to evaluate biochemical responses and metabolic pathways in CNS disease (2) . However, the metabolomics profile after traumatic brain injury (TBI)-an important cause of mortality and morbidity in humans (3)-has not been investigated (4) . In TBI, the primary impact onto the brain and/or disruption of brain tissue is followed by secondary biochemical processes including a surge in excitatory amino acids, glycolysis, oxidative stress, and mitochondrial dysfunction (5) . Given that cerebrospinal fluid (CSF) provides a window into the CNS, evaluation of metabolomics signatures in CSF after TBI and identification of biochemical pathways altered in response to injury could uncover new and validate suspected pathophysiologic mechanisms in humans and define clinically relevant therapeutic targets. In addition, evaluation of CSF metabolites could also be used to determine the holistic effects of pharmacotherapies, including target engagement or potential toxicity.
Although there are many regulators of the biochemical milieu of the brain at the blood-brain barrier (BBB) and blood-CSF barriers, membrane transporters such as adenosine triphosphate-binding cassette (ABC) transporters and solute carriers (SLCs) such as organic anion transporters (OATs) are particularly important in terms of brain bioavailability of clinically used drugs, especially those that do not readily cross the BBB. Probenecid is a promiscuous SLC and ABC transporter inhibitor that has been used to identify CSF elimination pathways for endogenous organic acids and monoamines such as homovanillic acid and serotonin (6) and exogenous drugs such as methotrexate (7) and N-acetylcysteine (NAC) (8) .
We recently reported the repurposed use of probenecid and NAC (Pro-NAC) in a randomized, placebo-controlled phase I trial after severe TBI in children to capitalize on this drug interaction (9) . The goal of achieving measurable NAC in the CSF was achieved, and adverse events attributable to the drug (NAC)/drug adjuvant (probenecid) combination were not identified. Although the Pro-NAC study was the first use of probenecid as an adjuvant for a potential neuroprotective drug, in this case NAC, and the first pharmacokinetic trial in severe pediatric TBI, it was a phase I study and not powered to evaluate outcome or effects on intracranial pressure. CSF collected as part of the Pro-NAC trial did however provide an opportunity for a pharmacometabolomics interrogation of the CNS after TBI. Accordingly, the purpose of the present study was to evaluate metabolomics changes in human TBI versus control subjects and to evaluate pharmacometabolomic changes in TBI patients treated with probenecid and NAC versus placebo.
MATERIALS AND METHODS

Parent Study
Samples for this study represent CSF obtained from patients who participated in a randomized, double-blind, phase I study (Trial Registration NCT01322009) of the combination of probenecid and NAC (n = 7) versus placebo (n = 5) in children 2-18 years old after severe TBI (Glasgow Coma Scale score ≤ 8) recruited from November 2011 to September 2013 at a single, tertiary children's hospital (9) . The study was approved by the University of Pittsburgh Institutional Review Board, and informed consent was obtained from parents and/or legal guardians of all children enrolled in the study. Control CSF samples were obtained from five age-matched control subjects who underwent lumbar puncture to rule out meningitis.
Sample Collection
CSF samples for this study were collected 41.7 hours (range, 34-47.25 hr) after injury and 24 hours after the first dose of probenecid (25 mg/kg) and NAC (140 mg/kg). Drugs or placebo were administered via naso/orogastric tube. CSF was immediately centrifuged at 3,000 × g for 10 minutes, and supernatant was aliquoted and stored at -80°C for batch analysis.
Ultra-Performance Liquid Chromatography Coupled
With Quadrupole Time-of-Flight Mass Spectrometry Analysis CSF samples were prepared by first precipitating protein with acetonitrile at a 3:1 ratio followed by centrifugation. Five microliters of supernatant was analyzed by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS; Synapt G2-S Waters, Milford, MA). An acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 µm; Waters, Milford, MA) was used to separate metabolites. The flow rate of the mobile phase was 0.5 mL/min using a gradient ranging from 2% to 98% acetonitrile/water containing 0.1% formic acid over 12 minutes. The column temperature was maintained at 50°C. Time-of-flight mass spectrometry (TOFMS) was operated in positive and negative modes with electrospray ionization. The source and desolvation temperatures were set at 150°C and 500°C, respectively. Nitrogen was applied as cone and desolvation gas, and the gas flow rates were set as 50 and 800 L/hr, respectively. Capillary and cone voltages were set at 0.8 kV and 40 V, respectively. TOFMS was calibrated with sodium formate and monitored by the intermittent injection of lockspray leucine encephalin in real time. MS data were acquired in centroid format over a range of 50-1,000 daltons with an acquisition time of 0.1 seconds per scan.
Metabolomics Analysis
The XCMS-online metabolomics platform (Scripps Research Institute, San Diego, CA) was used for data management and analysis including feature detection, retention time correction, alignment, annotation, principal component analysis (PCA), statistical analysis, and data visualization (10) (11) (12) (13) (14) . Raw data files were converted to mzData files using ms2mz, uploaded to XCMS-online and processed in positive and negative MS modes. Both positive and negative MS modes for ionization of sample molecules were used to capture and analyze metabolites which otherwise would have been ionized in only one of the two settings. A multigroup experiment was performed to compare all groups simultaneously. Pair-wise experiments were performed to compare control subjects versus placebotreated TBI groups and placebo-treated TBI versus probenecid and NAC-treated TBI groups.
For data analysis with XCMS-online, the centWave method was used for feature detection with 15 ppm m/z tolerance, minimum peak width of 2 seconds, and maximum peak width of 25 seconds. The Obiwarp function was used for retention time correction. Chromatogram alignment was performed with an mz width of 0.1, minimum fraction of 0.05, and bandwidth of 2. Isotopes and adducts were annotated using Collection of Algorithms for Metabolite Profile Annotation (Bioconductor; bioconductor.org) with an m/z absolute error of 0.015 and 5 ppm. Selection and filtering of metabolite features for inclusion in pathway/network analyses were done based on a foldchange greater than or equal to 1.5 and p value of less than or equal to 0.01. Metabolites were identified by searching the Human Metabolome Database (HMDB) with 10 ppm error margin.
Pathway and Network Analysis
Network and pathway analyses were performed using "Mummichog" (Emory University, Atlanta, GA) which is incorporated within the XCMS-online platform (15) . We conducted both pathway and network analyses because the methods are complimentary to each other and identify biochemical processes of interest independently. Pathways represent well-established biochemical processes that in general allow for intuitive interpretation. On the other hand, networks are derived from large-scale genomic, proteomic, or other systems level biological data where interpretation is less intuitive. However, networks are less biased and provide information not attained in pathways (16, 17) . Significant metabolite features in the pair-wise comparisons were used as input, and the total list of features were used as reference. For the pathway analysis, the enrichment of input metabolites against random data resampled from the reference list (in the background of known human metabolic pathways) provided adjusted p values while accounting for the fact that single m/z values can map to different metabolites and different m/z features can represent a single metabolite. Network analysis was done in a similar way except that compounds are placed within the human metabolic network model. Modules are defined as subsets within the network that show more connectivity and interrelationship than what is expected randomly in the network as a whole and are identified by their interconnectivity. Output data from the network analysis were imported to Cytoscape 3.4.0 (18) to generate network visualization. Excel 2013 (Microsoft Corporation, Redmond, WA) was used to generate cloud plots of the impacted pathways. R-Studio 1.0.136 (www.r-project.org) was used to generate volcano plots of metabolite features.
Statistical Analysis
Statistical analysis of metabolomics data using the XCMSonline platform is described in the study by Gowda et al (11) . Briefly, multigroup differences used for PCA and box plots were determined by one-way analysis of variance with Tukey post hoc test. An unpaired Welsh t test was used to assess differences between 1) control subjects versus placebo-treated TBI groups and 2) placebo-treated TBI versus probenecid and NAC-treated TBI groups, visualized in cloud and volcano plots. A p value of less than or equal to 0.01 was considered significant. A fold-change greater than or equal to 1.5 was also required for inclusion in pathway and network analyses.
RESULTS
Patient Characteristics
In the parent study, 14 patients were randomized to probenecid and NAC (n = 7) or placebo groups (n = 7) (9). Residual CSF was available from 12 patients collected 24 hours after the first drug or placebo administration, seven in the probenecid and NAC, and five in the placebo groups. Demographic characteristics are summarized in Table S1 (Supplemental Digital Content 1, http://links.lww.com/CCM/D599).
Multigroup Metabolomics Analysis
Multigroup analysis was performed to compare the CSF metabolomics profiles of control subjects, TBI patients administered placebo, and TBI patients treated with probenecid and NAC. Two-component PCA revealed clustering within each of the groups and separation between groups (Fig. 1) .
Pair-Wise Analysis of Control Subjects Versus Placebo-Treated TBI Patients
To detect metabolites that are altered in response to TBI, CSF from placebo-treated TBI patients and control subjects were compared. Using m/z-retention time plots, 1,010 features in the positive MS mode ( Fig. 2A) and 89 features in the negative MS mode (Fig. 2B ) that were significantly increased or decreased were identified (p ≤ 0.01, fold-change ≥ 1.5). The majority of features appeared to decrease in TBI patients versus control subjects.
We next sought to identify individual metabolites of interest altered in control subjects versus placebo-treated TBI patients. Metabolites with maximum absolute intensity greater than or equal to 2,500, -log(p) greater than 3, and log 2 (foldchange) greater than 1 were selected for identification ( masses were searched in the HMDB (15, 19, 20) . Excluding putative metabolites that were of dietary or exogenous drug source yielded endogenous metabolites with a previously known or biologically plausible association with TBI. Putative metabolites in 19 of these features corresponded to long-chain fatty acids; however, because of the difficulty distinguishing among analogues with the same m/z, these were not further characterized. The final list of 10 features and their corresponding TBIassociated metabolites are shown in Table S2A (Supplemental Digital Content 3, http://links.lww.com/CCM/D601). Of potential interest are changes in multiple species of gangliosides, ceramide, and dipeptides in TBI patients versus control subjects.
Pair-Wise Analysis of TBI Patients Receiving Probenecid and NAC Versus Placebo
To elucidate the impact of probenecid and NAC treatment on the CSF metabolomics profile after TBI, placebo-and Pro-NAC-treated TBI patients were compared. Using m/z-retention time plots, 153 features in the positive MS mode (Fig. 2C) and 296 features in the negative MS mode (Fig. 2D ) that were significantly increased or decreased were identified. In contrast to control subjects versus TBI patients, the majority of features appeared to increase in patients treated with probenecid and NAC versus placebo.
We next sought to identify individual metabolites of interest altered in TBI patients receiving probenecid and NAC versus placebo. Metabolites with maximum absolute intensity greater than or equal to 2,500, -log(p) greater than 2.3, and log 2 (fold-change) greater than 1 were selected for possible identification (Fig. S1 Glutathione was also increased in probenecid-and NAC-treated patients versus placebo, consistent with drug combination target engagement.
Internal Validity
As a means of internal validation, we evaluated the study drug probenecid and phenytoin (administered to 11/12 TBI patients for seizure prophylaxis). Searching for either the parent drugs or metabolites of probenecid and phenytoin among the putative metabolites shows matching features with expected differential abundance in the three groups (Fig. S1 , Supplemental Digital Content 2, http://links.lww.com/CCM/D600; legend, Supplemental Digital Content 11, http://links.lww.com/CCM/D609). In addition, the peak area of probenecid determined by UPLC-QTOFMS correlated with previously quantified probenecid concentrations (r 2 = 0.76, p = 0.01) determined by ultra-performance liquid chromatography -tandem mass spectrometry (9) .
Pathway Analysis of Control Subjects Versus Placebo-Treated TBI Patients
We conducted pathway analysis of CSF metabolites in placebo-treated TBI patients versus control subjects. Metabolites that were significantly changed in response to TBI were enriched in six pathways in the positive MS mode and 17 pathways in the negative MS mode ( Fig. 3; Table S3 , Supplemental Digital Content 4, http://links.lww.com/CCM/D602; and Table S4 , Supplemental Digital Content 5, http://links. lww.com/CCM/D603).
Pathway Analysis of TBI Patients Receiving Probenecid and NAC Versus Placebo
Pathway analysis was performed to identify biochemical processes modified by probenecid and NAC treatment after TBI. In the positive MS mode, a total of 77 pathways were enriched in metabolites that were differentially dysregulated between the two groups, with 45 pathways showing greater than or equal to 50% overlap between putative metabolites with a known component of the particular pathway. In the negative MS mode, a total of 47 pathways were found to be significantly dysregulated, with eight pathways showing greater than or equal to 50% overlap between putative metabolites ( Fig. 4; Table S5 , Supplemental Digital Content 6, http://links.lww.com/CCM/D604; and Table S6 , Supplemental Digital Content 7, http://links.lww. com/CCM/D605).
Network Analysis of TBI Patients Receiving Probenecid and NAC Versus Placebo
Network analysis identified five modules that are significantly affected by probenecid and NAC treatment in the positive MS mode and four modules in the negative MS mode. Modules represent internal connectivity greater than what is expected randomly in the network. Some modules identified are nested, that is, bigger module consists of smaller, independent modules. The complete list of putative metabolites that constitute the modules are in Supplemental Table S7 (Supplemental Digital Content 8, http://links.lww.com/CCM/D606) and Table S8 (Supplemental Digital Content 9, http://links.lww.com/CCM/D607). Notable features of these modules include up-regulation of glutathione and its conjugates (Fig. 5) ; up-regulation of donors in sulfate conjugation and metabolites with sulfate conjugation characteristics (Fig. S2A , Supplemental Digital Content 10, http:// links.lww.com/CCM/D608; legend, Supplemental Digital Content 11, http://links.lww.com/CCM/D609) that are confirmed substrates of probenecid-inhibitable transporters (21); a collective down-regulation of prostaglandins (Fig. S2B , Supplemental Digital Content 10, http://links.lww.com/CCM/D608; legend, Supplemental Digital Content 11, http://links.lww.com/ CCM/D609) which are also known to be substrates of probenecid-inhibitable transporters (22); 2-ketoglutarate, which interacts with probenecid-inhibitable OAT1 (8, 23) ; kynurenate, 3-hydroxykynurenine, and dipeptides that share substrates of OAT transporters (24-27); and up-regulation of uridine diphosphate-conjugated monosaccharides and down-regulation of their interacting counterparts, acetylated sugar moieties. Transporters responsible for the translocation of these sugar nucleotides are known to be sensitive to inhibition by probenecid (25, 28) .
DISCUSSION
To our knowledge, this is the first study to perform a comprehensive metabolomics analysis in TBI patients and the first clinical application of "neuropharmacometabolomics" after administration of potentially therapeutic drugs, including probenecid which is well known to impact the biochemical milieu of the CSF (6, 7). We focused on pathway and network analysis of the metabolomics data, leveraging recent advances that enable exploration without exhaustive verification of individual metabolites (15). Pathway analysis (16) revealed novel biochemical processes associated with TBI, while also confirming others with a previously known role. Treatment with probenecid and NAC resulted in a significant alteration in the metabolomics signature of TBI, with the majority of features showing relative increases versus placebo. Importantly, relative glutathione levels were increased, and both pathway and network analyses showed that biochemical processes involving detoxification with glutathione and glutathione recycling were enriched in the probenecid-and NAC-treated group, consistent with target engagement of at least one of the components of the combination therapy. Furthermore, modules and pathways with components known to be substrates of transporters inhibited by probenecid were identified.
Comparing the TBI placebo-treated patients with the control subjects revealed several biochemical pathways altered after TBI. Previous studies have reported TBI-related catabolism of numerous small molecules including amino acids, catecholamines, hormones, and polyamines. Components of a number of these molecular pathways were amplified after TBI, including tyrosine, noradrenaline/adrenaline, spermine/spermidine, and nicotine degradation; thyroid hormone conjugation and/or degradation; and L-carnitine biosynthesis. Other pathways found to be enriched that are implicated in the pathophysiology of TBI include oxidative stress (alpha-tocopherol degradation, ubiquinol-10 biosynthesis), bioenergetics (lactate fermentation pathway), lipid peroxidation (leukotriene and resolvin-D biosynthesis), and heme metabolism (tetrapyrrole and heme biosynthesis). Cystathionine-β-synthase, which catalyzes the first step in the transulfuration of homocysteine to cystathionine, has been reported to mediate pathologic processes after TBI (29) . Cysteine biosynthesis/ homocysteine degradation and hydrogen sulfide biosynthesis were also found to be up-regulated.
Some of the enriched pathways uncovered had not been associated with TBI, for example, morphine biosynthesis. Endogenous morphine biosynthesis by human neuroblastoma cells has been reported (30, 31) , and the activation of this pathway in TBI patients may indicate a role in pain modulation after injury. Two methylglyoxal-related pathways were found to be up-regulated in TBI patients. Methylglyoxal, a potentially toxic byproduct of glycolysis, threonine catabolism, and lipid peroxidation has been implicated in models of cerebral ischemia (32, 33) . Also in the present study, pathways related to purine and pyrimidine metabolism were enriched, reported to mediate activation of astrocytes and other glia in acute and chronic neuroinflammation (34) .
Treatment with a combination of probenecid and NAC resulted in significant changes in the metabolomics signature in CSF after TBI. Pathway and network analyses revealed over 80 pathways and nine modules, respectively, that were dysregulated in the treatment group versus placebo. Seven pathways that involve glutathione as a component of detoxification processes were enhanced in the treatment group: glutathione redox reactions I and II, 4-hydroxy-2-nonenal and arsenate detoxification, methylglyoxal degradation, ascorbate recycling, and formaldehyde oxidation. These observations were congruent with network analysis which featured glutathione-centered modules. These findings provide validity to the metabolomicsbased pathway and network analyses, given that probenecid and NAC can increase glutathione via preventing cellular efflux of glutathione disulfide and glutathionylated xenobiotics, and serving as a cysteine donor for glutathione synthesis, respectively. Furthermore, NAC is a substrate for probenecid-inhibitable OATs (8) . Collectively, our findings are consistent with combination treatment with probenecid and NAC increasing glutathione and its conjugates, suggestive of target engagement.
Other prominent pathways/biochemical processes possibly altered by treatment include purine and pyrimidine metabolism; catabolism, salvage, and biosynthesis of amino acids; catecholamines; hormones; peptides and polyamines; oxidation, degradation, and biosynthesis of fatty acids and lipids; glycolysis; and aerobic cellular respiration. This suggests that many biochemical substrates, intermediates, and end products may be substrates of probenecid-inhibitable transporters. Some components of the enriched pathways and modules such as urate (35) ; kynurenate, xanthurenate, and indoxyl sulfate (24, 25) ; cyclic nucleotides (36); and prostaglandins (22) are known substrates. Additionally, a module centered around 2-ketoglutarate, which acts as a gradient exchanger in the transport of organic anions by OATs, was identified (37) .
Many alterations in the biochemical milieu observed in probenecid and NAC-treated versus placebo-treated TBI patients can be explained by the known properties of probenecid. Some of these changes, such as increased abundance of kynurenine, may be beneficial after TBI. Kynurenine has been studied in combination with probenecid to attenuate seizures, quinolinic acid-induced neurotoxicity, and neuropathic pain (38) (39) (40) . Other effects may be undesirable, for example, increased indoxyl sulfate (a uremic toxin) which has been linked to CNS toxicity in patients with impaired kidney function (41) .
Initial screening yielded 10 features in CSF that distinguished TBI patients from control subjects. Subsequent querying of the HMDB showed that gangliosides appear as putative metabolites in four of 10 features, consistent with a role for gangliosides in TBI (42, 43) . Comparing placebo and probenecid-and NACtreated TBI patients yielded 24 putative metabolites. Congruent with pathway and network analyses, glutathione and its conjugates were commonly featured. As these are exploratory findings, feature verification and further evaluation are necessary.
Although this study does represent the first comprehensive metabolomics analysis of any kind in human TBI, sample sizes are limited. However, the number of subjects was sufficient to clearly discriminate between groups using PCA (Fig. 1) . We chose to study individual versus pooled samples despite the risk of increased sample variation and cost of analysis, in order to take advantage of pathway and network analysis (16, 17) . One advantage of using a multimodal approach, supplementing individual feature identification with pathway and network analysis, is that the likelihood of false discovery when examining multiple feature enrichment within select pathways and/ or networks is lower than when identifying individual features alone, an important consideration when large numbers of statistically significant features are detected. It was partially confirmatory that many individual features identified clustered into known biological pathways and/or networks. From a technical standpoint, the samples were precipitated with acetonitrile, thus the analytical approach did not identify proteins. Finally, other than probenecid measurements, which were tightly correlated with previously published concentrations determined by UPLC-MS/MS (9), individual metabolites/features and pathways were not confirmed independently.
CONCLUSIONS
Advanced analysis of metabolomics data revealed pathways and networks that are dysregulated after TBI. Some of these pathways have known involvement, whereas others represent novel findings, potentially bringing new insights into the pathogenesis of TBI. Similarly, treatment with a combination of probenecid and NAC resulted in enrichment of numerous pathways and networks (including several glutathione-related pathways) supporting the a priori hypothesis for using this drug combination in TBI. Furthermore, several individual features, pathways, and networks with biologically plausible interactions consistent with probenecid and/or NAC therapeutic target engagement were identified. This proof-of-concept study demonstrates that neuropharmacometabolomics may represent a powerful tool for developing a comprehensive understanding of the multiple biochemical processes and mechanisms involved in the pathogenesis of TBI and the effects of pharmacologic interventions.
